Replimune Group Inc (REPL)
$11.29
Live
Performance
- $11.13$11.59$11.29
1.42%
Downside
Day's Volatility :3.97%
Upside
2.59%
- $4.92$15.33$11.29
56.42%
Downside
52 Weeks Volatility :67.91%
Upside
26.35%
Returns
| Period | Replimune Group Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 17.17% | 3.6% | 0.0% |
6 Months | 79.6% | 10.2% | 0.0% |
1 Year | -15.5% | 19.6% | 0.0% |
3 Years | -60.16% | 16.8% | -23.0% |
Highlights
Market Capitalization | 772.7M |
Book Value | $6.24 |
Earnings Per Share (EPS) | -3.27 |
Wall Street Target Price | 15.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -25.74% |
Return On Equity TTM | -46.79% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -231.8M |
Diluted Eps TTM | -3.27 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.27 |
EPS Estimate Next Year | -3.03 |
EPS Estimate Current Quarter | -0.85 |
EPS Estimate Next Quarter | -0.84 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 37.29%
Technicals Summary
Sell
Neutral
Buy
Replimune Group Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Replimune Group Inc | 5.2% | 79.6% | -15.5% | -60.16% | -21.88% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Replimune Group Inc | NA | NA | NA | -3.27 | -0.47 | -0.26 | NA | 6.24 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Replimune Group Inc | Buy | $772.7M | -21.88% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Replimune Group Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 105.2%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 105.0%
Institutional Holdings
Baker Bros Advisors LP
14.70%T. Rowe Price Associates, Inc.
13.52%Redmile Group, LLC
8.14%FCPM III SERVICES BV
7.12%BlackRock Inc
6.90%Millennium Management LLC
4.56%
Company Information
replimune group, inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. it uses its proprietary immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. the company's lead product candidate is rp1, a selectively replicating version of herpes simplex virus 1, which is in phase i/ii clinical trials for a range of solid tumors; and that is in phase ii clinical trials for patients with cutaneous squamous cell carcinoma. it is also developing rp2, which is in phase i clinical trials for an anti-ctla-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by ctla-4; and rp3 to express immune-activating proteins that stimulate t cells. replimune group, inc. was founded in 2015 and is headquartered in woburn, massachusetts.
Organization | Replimune Group Inc |
Employees | 331 |
CEO | Mr. Philip Astley-Sparke F.S.A. |
Industry | Health Technology |
Discover More
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$11.29
-2.08%
Invesco Bulletshares 2025 Hi
$11.29
-2.08%
Schwab International Dividend Equity Etf
$11.29
-2.08%
Blockchain Coinvestors Acquisition Corp.
$11.29
-2.08%
Allgiant Travel Company
$11.29
-2.08%
Rogers Corp
$11.29
-2.08%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$11.29
-2.08%
Iheartmedia
$11.29
-2.08%
Lightpath Technologies Inc
$11.29
-2.08%